Patent details

300844 Product Name: Ibrutinib, of een farmaceutisch aanvaardbaar zout ervan

The time of generation of the report may vary depending on the number of the selected files and the pages of each file. If the generation of the consolidated PDF file takes long, you may reduce the number of selected files and proceed with the generation of the PDF in batches.
You have not selected any documents

Basic Information

Publication number:
300844
Type:
Certificate
SPC Type:
Medical
Basic Patent Number:
EP2526934
Status:
Refused Art. 10 of the EC Regulations
Application number:
300844
Procedural language:
Dutch
First Applicant Residence Country:
United States of America (US)

Marketing Authorization

Marketing Authorization Number:
EU/1/14/945 - C(2016)3293
Marketing Authorization Type:
EEA
Marketing Authorization Date:
30/05/2016
Marketing Authorization Country:
European Union (EU)

Dates

Filing date:
23/11/2016
First Marketing Authorization date:
30/05/2016
Grant date:
Activation date:
Lapsed By Non Payment Annual Fee Date:
Renunciation Date:
NullificationDate:
Registration date:
24/11/2016
SPC/SPC Extension Expiration Date:
Lapsed By Expiration Date:
Withdrawal date:
Revocation Date:
Invalidity Date:
Withdrawal Market Authorization Date:
Refusal Date:
10/11/2020

Applicant/holder

From:
24/11/2016
 
 

 

Name:
Pharmacyclics LLC
Address:
995 East Arques Avenue, Sunnyvale, CA 94085, United States of America (US)

Agent

Name:
ir. M.F.J.M. Ketelaars c.s.
From:
24/11/2016
Address:
NLO Postbus 29720, 2502 LS, Den Haag, Netherlands (NL)
To:

Publication

Bulletin

1

Bulletin Heading:
VRV
Journal edition number:
46/20
Publication date:
11/11/2020
Description:
Lapse or annulment

2

Bulletin Heading:
SPC
Journal edition number:
48/16
Publication date:
30/11/2016
Description:
Applications and granted Supplementary Protection Certificates (or the extensions of the Supplementary Protection Certificates)
Filing date Document type Document Description Number of pages File Type
10/11/2020 Outgoing Correspondence Decision refusal 2 PDF /1/9/0/0/1/0800110091/docs/300844_6_376217l527a.pdf
28/07/2020 Outgoing Correspondence Letter to applicant 3 PDF /1/9/0/0/1/0800110091/docs/300844_1_outgoingcorrespondence20200728123121031.pdf
25/11/2016 Outgoing Correspondence Confirmation receipt request 1 PDF /1/9/0/0/1/0800110091/docs/300844_3_100098l174.pdf
23/11/2016 SPC Documents Annex SPC 2 PDF /1/9/0/0/1/0800110091/docs/300844_0_supplprotectioncertificate20200420035534627.pdf
23/11/2016 Application Form First filed application form 3 PDF /1/9/0/0/1/0800110091/docs/300844_2_applicationform20161124032354989.pdf
23/11/2016 SPC Documents Summary of the characteristics of the product 19 PDF /1/9/0/0/1/0800110091/docs/300844_4_supplprotectioncertificate20161124032355376.pdf
23/11/2016 SPC Documents Accompanying letter SPC 3 PDF /1/9/0/0/1/0800110091/docs/300844_5_supplprotectioncertificate20210406023549333.pdf
23/11/2016 SPC Documents Marketing Authorization SPC 3 PDF /1/9/0/0/1/0800110091/docs/300844_7_supplprotectioncertificate20161124032355464.pdf